Breakthrough invasive mould infections in patients treated with caspofungin

Journal of Infection

Volumn 64, Issue 4, 2012, Pages 424-429

  Phai Pang, Katy Anna ^a   Godet, Cendrine ^b   Fekkar, Arnaud ^c   Scholler, Julie ^a   Nivoix, Yasmine ^a   Letscher Bru, Valérie ^d   Massias, Laurent ^e   Kauffmann Lacroix, Catherine ^b   Elsendoorn, Antoine ^b   Uzunov, Madalina ^c   Datry, Annick ^c   Herbrecht, Raoul ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

Acute leukaemia; Caspofungin; Fusarium; Haematopoietic stem cell transplantation; Invasive pulmonary aspergillosis; Mucormycosis

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; VORICONAZOLE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDEMIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; FEMALE; FUSARIOSIS; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RATE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOULD; MUCORMYCOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION;

ADULT; AGED; ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FRANCE; FUSARIOSIS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS, UNIVERSITY; HUMANS; MALE; MANNANS; MIDDLE AGED; MUCORMYCOSIS; PULMONARY ASPERGILLOSIS;

EID: 84858441721     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.12.015     Document Type: Article

References (26)

1. Letscher-Bru V., Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003, 51:513-521.
2. Arendrup M.C., Garcia-Effron G., Buzina W., Mortensen K.L., Reiter N., Lundin C., et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009, 53:1185-1193.
3. Eschertzhuber S., Velik-Salchner C., Hoermann C., Hoefer D., Lass-Florl C. Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transpl Infect Dis 2008, 10:190-192.
4. Lafaurie M., Lapalu J., Raffoux E., Breton B., Lacroix C., Socie G., et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 2010, 16:1191-1196.
5. Madureira A., Bergeron A., Lacroix C., Robin M., Rocha V., de Latour R.P., et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007, 30:551-554.
6. Pavie J., Lacroix C., Hermoso D.G., Robin M., Ferry C., Bergeron A., et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005, 43:4902-4904.
7. de Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
8. Segal B.H., Herbrecht R., Stevens D.A., Ostrosky-Zeichner L., Sobel J., Viscoli C., et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008, 47:674-683.
9. Nivoix Y., Zamfir A., Lutun P., Kara F., Remy V., Lioure B., et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006, 52:67-74.
10. Akagi T., Yamaguti K., Kawamura T., Nakumura T., Kubo K., Takemori H. Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk Lymphoma 2006, 47:1182-1183.
11. Bayramoglu G., Sonmez M., Tosun I., Aydin K., Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 2008, 36:68-70.
12. Goodman D., Pamer E., Jakubowski A., Morris C., Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002, 35:E35-E36.
13. Matsue K., Uryu H., Koseki M., Asada N., Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006, 42:753-757.
14. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., Perfect J.R., Perlin D.S., Alexander B.D. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010, 48:2373-2380.
15. Schuermans C., van Bergen M., Coorevits L., Verhaegen J., Lagrou K., Surmont I., et al. Breakthrough Saprochaete capitata infections in patients receiving echinocandins: case report and review of the literature. Med Mycol 2011, 49:414-418.
16. Suzuki K., Nakase K., Ino K., Sugawara Y., Sekine T., Katayama N. Breakthrough cryptococcosis in a patient with systemic lupus erythematosus (SLE) receiving micafungin. J Infect Chemother 2008, 14:311-314.
17. Tascini C., Urbani L., Doria R., Catalano G., Leonildi A., Filipponi F., et al. Breakthrough Fusarium spp fungemia during caspofungin therapy in an ABO-incompatible orthotopic liver transplant patient. J Chemother 2009, 21:236-238.
18. Wetzstein G.A., Green M.R., Greene J.N. Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases. J Infect 2007, 55:e131-e133.
19. Chamilos G., Kontoyiannis D.P. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005, 8:344-358.
20. Imhof A., Balajee S.A., Fredricks D.N., Englund J.A., Marr K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743-746.
21. Trifilio S., Singhal S., Williams S., Frankfurt O., Gordon L., Evens A., et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451-456.
22. Li C.C., Sun P., Dong Y., Bi S., Desai R., Dockendorf M.F., et al. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob Agents Chemother 2011, 55:2098-2105.
23. Marr K.A., Balajee S.A., McLaughlin L., Tabouret M., Bentsen C., Walsh T.J. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004, 190:641-649.
24. Viscoli C., Herbrecht R., Akan H., Baila L., Sonet A., Gallamini A., et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009, 64:1274-1281.
25. Herbrecht R., Maertens J., Baila L., Aoun M., Heinz W., Martino R., et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010, 45:1227-1233.
26. Betts R.F., Nucci M., Talwar D., Gareca M., Queiroz-Telles F., Bedimo R.J., et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48:1676-1684.